

Subject: Medical Science Liaison (MSL) Notes - Mixed Discussion on Revitalizix

Date: December 7, 2023

Provider: Dr. Amanda Martinez

Title: Cardiologist

Institution: Metropolitan Heart Center

Summary of Key Discussion Points:

1. Introduction:

- Introduced Revitalizix as a potential therapy for heart failure with preserved ejection fraction.
- Dr. Martinez expressed cautious optimism, acknowledging the need for additional treatment options in heart failure.

2. Provider's Current Patient Cases:

- Shared positive experiences with Revitalizix in some patients, noting improvements in exercise tolerance.
- Discussed challenges in achieving consistent responses, citing cases with minimal observable benefits.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing Revitalizix's improvements in left ventricular diastolic function.
- Dr. Martinez acknowledged the statistically significant improvement but questioned the practical impact on patients' daily lives.

4. Safety Profile:

- Discussed the favorable safety profile of Revitalizix based on reported adverse events.
- Dr. Martinez raised concerns about potential long-term safety, particularly in elderly patients with multiple comorbidities.

5. Mechanism of Action:

- Explained Revitalizix's mechanism targeting myocardial stiffness and inflammation.
- Dr. Martinez appreciated the drug's novel approach but expressed a desire for more detailed mechanistic data.

6. Patient Adherence and Education:

- Dr. Martinez recognized the importance of patient education in optimizing adherence to Revitalizix.
- Discussed challenges in motivating patients when perceived benefits vary.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on Revitalizix's potential applications in heart failure subtypes.
- Dr. Martinez expressed interest in participating in clinical trials focused on specific patient populations.

8. Competitive Landscape:

- Compared Revitalizix to existing heart failure therapies, acknowledging its potential niche.
- Discussed the need for head-to-head trials to better understand the drug's comparative effectiveness.

9. Access and Reimbursement:

- Dr. Martinez acknowledged the importance of access and affordability for patient populations.
- Raised concerns about potential disparities in access based on healthcare settings.

10. Action Items and Follow-Up:

- Dr. Martinez expressed interest in receiving updates on real-world evidence studies for Revitalizix.
- Agreed upon a follow-up in two months to provide additional data and address any ongoing concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Martinez's thoughtful insights and willingness to engage in ongoing discussions.
- Reiterated commitment to transparency and collaboration in advancing cardiovascular care with Revitalizix.